Showing 2201-2210 of 7668 results for "".
- Tik Tok Trend Watch: Cyanide as a Potential Acne Cure?https://practicaldermatology.com/news/tik-tok-trend-watch-cyanide-as-a-potential-acne-cure/2461968/Tik Tok is where many trends and DIY challenges get started, and skin care one of the more popular categories for this content. The latest -- a viral video of a woman claiming that she has been 'secretly' feeding her boyfriend seeds containing cyanide (yes, that cyanide) and that it has cleared u…
- New CEO for SciBasehttps://practicaldermatology.com/news/new-ceo-for-scibase/2461967/Pia Renaudin is SciBase’s new Chief Executive Officer (CEO), effective October 1st, 2023. SciBase's products include Nevisense and Nevisense Go and address melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Ms. Renaudin has spent more than 20 years in companies…
- POCN Launches AD Center of Excellencehttps://practicaldermatology.com/news/pocn-launches-ad-center-of-excellence/2461965/POCN has launched its Atopic Dermatitis Center of Excellence, a free online portal that provides NPs and PAs with clinical guidelines, patient support and education resources, and the latest clinical atopic dermatitis research. The information in the portal includes diagnostic tools, treatment su…
- Nathalie Daste Named LEO Pharma’s New Executive Vice President of Global People and Corporate Affairshttps://practicaldermatology.com/news/nathalie-daste-named-leo-pharmas-new-executive-vice-president-of-global-people-and-corporate-affairs/2461964/Nathalie Daste is LEO Pharma’s new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023. In her new role, Ms. Daste will head LEO Pharma’s Global People function as well as Corporate Affairs, including sustainability and…
- FUE Technique Shows Promise for Treating Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/fue-technique-shows-promise-for-treating-acne-keloidalis-nuchae/2461963/Follicular unit excision (FUE) may help treat acne keloidalis nuchae (AKN), according to research in the Journal of The American Academy of Dermatology – JAAD Case Reports. The study reports the first-time use of a FUE as a potential remedy for AKN in three patients. FUE targets individual hair fo…
- Cutera, Inc. Appoints Jeff Jones as COOhttps://practicaldermatology.com/news/cutera-inc-appoints-jeff-jones-as-coo/2461956/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, field service engineering, and…
- Simpson Lab Awarded $50k Grant from Foundation for Ichthyosis & Related Skin Typeshttps://practicaldermatology.com/news/simpson-lab-awarded-50k-grant-from-foundation-for-ichthyosis-related-skin-types/2461955/Cory Simpson, MD, PhD, received a one-year $50k grant from the Foundation for Ichthyosis & Related Skin Types (FIRST) to support the Simpson Lab’s ongoing research in epidermal differentiation and skin disease. Funding from this award will support Simpson Lab personnel and provide supplies for res…
- Conagen Introduces Novel Natural-source Retinol for Cosmetic Formulationshttps://practicaldermatology.com/news/conagen-introduces-novel-natural-source-retinol-for-cosmetic-formulations/2461951/Conagen is unveiling a new natural-sourced class of sustainable retinol derivative ingredients madevia precision fermentation. “Conagen is ready to commercialize these retinoid ingredients in 2024,” says Yisheng Wu, PhD. VP of Flavors and Fragrances, at Conagen, in a news release. Conagen’s r…
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation from the U.S. Food and Drug Ad…
- Dove Gives Back With the Dove Nature Regeneration Projecthttps://practicaldermatology.com/news/dove-gives-back-with-the-dove-nature-regeneration-project/2461947/Dove is introducing their Nature Regeneration Project, a new initiative to protect nature and tackle climate change. In partnership with the Rimba Collective, Dove will help protect and restore 123,000 acres of rainforest in Southeast Asia –an area 8x the size of Manhattan – over five years. "…